Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia

Antonio M. Gotto, Jennifer Moon

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Pitavastatin is a new, synthetic member of the statin class of lipid-lowering drugs. Compared with other available statins, it has a unique cyclopropyl group on its base structure that is believed to increase 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition by a factor of five and to significantly increase the transcription and activity of LDL receptors. Pitavastatin is primarily metabolized via glucuronidation and is not a substrate for the cytochrome P450 3A4 enzyme, thus avoiding the potential for cytochrome P450-mediated drug-drug interactions. Clinical trials have shown that pitavastatin is comparable to atorvastatin and simvastatin in improving lipid measures, and more potent than pravastatin. Pitavastatin is effective in reducing triglycerides and increasing HDL-cholesterol, so it will be particularly beneficial in treating patients with mixed dyslipidemia. Its safety and adverse event profile is similar to that of other available statins, and it has an established history of use in Asia indicating tolerability and safety for treatment lasting up to 7 years.

Original languageEnglish (US)
Pages (from-to)1079-1090
Number of pages12
JournalExpert Review of Cardiovascular Therapy
Issue number8
StatePublished - Aug 2010


  • cholesterol
  • coronary heart disease
  • dyslipidemia
  • HMG-CoA reductase inhibitors
  • LDL
  • pitavastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine


Dive into the research topics of 'Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia'. Together they form a unique fingerprint.

Cite this